Skip to main content
. 2020 Jul 29;72(9):1517–1525. doi: 10.1093/cid/ciaa1081

Table 1.

Characteristics of Patients at Baseline in the Modified Intention-to-Treat Population

Characteristic Daptomycin Plus Fosfomycin
(n = 74)
Daptomycin Alone
(n = 81)
Age, y, median (IQR) 74.0 (60.8–80.8) 72 (62.0–80.0)
Male sex 48 (64.9) 56 (69.1)
Charlson comorbidity index, median (IQR)a 3 (2–5) 4 (2–5.8)
Diabetes mellitusb 29 (30.3) 34 (41.9)
Diabetes mellitus with end organ damageb 13 (17.6) 18 (22.2)
Chronic kidney diseaseb 19 (25.7) 35 (43)
Congestive heart failureb 13 (17.6) 19 (23.4)
Malignancyb 18 (24.3) 16 (19.7)
Pitt score, mean (SD)c 1.15 (1.7) 1.22 (2.0)
Implants 20 (27.0) 27 (33.3)
 Orthopedic 11 (14.9) 13 (16.0)
 Pacemaker 8 (10.8) 4 (4.9)
Previous antibiotic therapyd 59 (79.7) 65 (80.2)
Acquisition
 Community-acquired 7 (9.4) 4 (4.9)
 Nosocomial infection 36 (48.6) 35 (43.2)
 Healthcare-associated 31 (41.8) 42 (51.8)
Main source of infection
 Intravascular catheter 31 (41.9) 39 (48.1)
 Skin and soft tissue infection 10 (13.5) 19 (23.5)
 Surgical site infection 7 (9.5) 4 (4.9)
 Urinary tract infection 6 (8.1) 3 (3.7)
 Unknown source 14 (18.9) 8 (9.9)
 Other 6 (7.4) 8 (9.9)
Echocardiography 53 (71.6) 59 (72.8)
Endocarditise 9 (12.2) 9 (11.1)
Days of therapy, median (IQR) 14 (11–21) 14 (10–18.5)

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: IQR, interquartile range; SD, standard deviation.

aProvides a 10-year mortality risk, based on weighted comorbid conditions.

bBased on the definitions within the Charlson comorbidity index assessment.

cProvides a measure of in-hospital mortality risk in patients with bloodstream infection based on clinical variables.

dBased on administration of any antibiotic in the 10 days prior to randomization.

eBased on assessment at test-of-cure visit according to modified Duke criteria [27].